OrbiMed’s Cooper Companies COO Stock Holding History

OrbiMed’s Portfolio COO Stock Details COO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-800,000	Closed	-$31.1M	–	134
2014 Q3	$31.1M	Buy	+800,000	New	+$31.5M	0.33%	57

Other funds holding COO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

AAMU

Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed's COO Position: Q2 2017 in Review

OrbiMed sold out of Cooper Companies (COO) in Q2 2017, closing a stake of 763,200 shares — an estimated $38.1M sold.

OrbiMed first reported a position in COO in Q3 2014 and held it in 11 quarters. The position peaked at $242M in Q1 2015. 454 funds tracked by Wall St. Rank hold COO as of Q2 2017.

OrbiMed reported no remaining Cooper Companies position as of Q2 2017 after selling out during the quarter.
OrbiMed sold 763,200 Cooper Companies shares in Q2 2017, an estimated $38.1M.
OrbiMed first reported a position in Cooper Companies in Q3 2014 and held it in 11 quarters.
OrbiMed's Cooper Companies position peaked at $242M in Q1 2015.
454 funds tracked by Wall St. Rank held Cooper Companies as of Q2 2017.

Based on OrbiMed's 13F filing for Q2 2017, filed 14 Aug 2017.